Biofrontera (BFRIW) Equity Average (2020 - 2025)

Biofrontera's Equity Average history runs 6 years deep, the most recent figure standing at $3.9 million for Q4 2025.

• In Q4 2025, Equity Average fell 20.72% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (down 20.72% YoY), while the FY2025 annual figure was $7.5 million, up 61.64% from the prior year.
• Equity Average was $3.9 million for Q4 2025 at Biofrontera, up from -$3.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $23.2 million in Q4 2022 to a low of -$9.4 million in Q3 2021.
• Historically, Equity Average has averaged $6.1 million across 5 years, with a median of $4.0 million in 2021.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 3641.79% in 2022, then plunged 175.85% in 2025.
• A 5-year view of Equity Average shows it stood at -$3.0 million in 2021, then soared by 869.17% to $23.2 million in 2022, then tumbled by 87.45% to $2.9 million in 2023, then surged by 70.86% to $5.0 million in 2024, then declined by 20.72% to $3.9 million in 2025.
• The last three Equity Average figures came in at $3.9 million (Q4 2025), -$3.6 million (Q3 2025), and -$2.1 million (Q2 2025), per Business Quant data.